Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma

卡波扎尼布 舒尼替尼 医学 克里唑蒂尼 临床终点 内科学 危险系数 乳头状肾细胞癌 肿瘤科 肾细胞癌 阿西替尼 帕唑帕尼 临床试验 泌尿科 置信区间 肺癌 恶性胸腔积液
作者
Pedro C. Barata,Catherine M. Tangen,Melissa Plets,Ian M. Thompson,Vivek Narayan,Daniel J. George,Daniel Yick Chin Heng,Brian Shuch,Mark N. Stein,Shuchi Gulati,Maria Tretiakova,Abhishek Tripathi,Georg A. Bjarnason,Peter A. Humphrey,Adebowale Adeniran,Ulka N. Vaishampayan,Ajjai Alva,Tian Zhang,Scott Cole,Primo N. Lara,Seth P. Lerner,Naomi B. Haas,Sumanta K. Pal
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
标识
DOI:10.1200/jco.24.00767
摘要

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of selected patients with papillary renal cell carcinoma (PRCC). In the phase II PAPMET trial (ClinicalTrials.gov identifier: NCT02761057 ), cabozantinib significantly prolonged progression-free survival and improved objective response rate compared with sunitinib in patients with advanced PRCC. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized phase II, open-label trial, 147 patients with advanced PRCC who have received up to one previous therapy (excluding vascular endothelial growth factor–directed agents) were assigned to sunitinib, cabozantinib, crizotinib, or savolitinib. Ultimately, savolitinib and crizotinib arms were closed because of futility. With a median follow-up of 17.5 months, the median OS was 21.5 months (95% CI, 12.0 to 28.1) with cabozantinib and 17.3 months (95% CI, 12.8 to 21.8) with sunitinib (hazard ratio, 0.83; 95% CI, 0.51 to 1.36; P = .46). The OS landmark estimates for cabozantinib and sunitinib were 50% versus 39% at 24 months and 32% versus 28% at 36 months. In conclusion, we observed no significant difference in OS across treatment arms. Although cabozantinib represents a well-supported option for advanced PRCC, the lack of survival benefit underscores the need to develop novel therapies for this disease.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
求助论文的人完成签到,获得积分10
1秒前
动听元正完成签到,获得积分10
2秒前
袅袅发布了新的文献求助10
3秒前
jj发布了新的文献求助10
3秒前
小丸子发布了新的文献求助10
3秒前
3秒前
huan_xii应助细心的梦芝采纳,获得20
4秒前
酱子完成签到,获得积分10
4秒前
小白痴发布了新的文献求助10
4秒前
Zon完成签到,获得积分10
5秒前
JamesPei应助wjx采纳,获得10
5秒前
风趣安青发布了新的文献求助10
6秒前
6秒前
无花果应助陌路孤星采纳,获得10
6秒前
齐俞如完成签到,获得积分10
7秒前
jennie发布了新的文献求助30
7秒前
sdl发布了新的文献求助10
7秒前
7秒前
酷波er应助科研通管家采纳,获得10
8秒前
清爽乐菱应助科研通管家采纳,获得30
8秒前
脑洞疼应助科研通管家采纳,获得10
8秒前
慕青应助科研通管家采纳,获得10
8秒前
赘婿应助科研通管家采纳,获得10
8秒前
科研通AI2S应助科研通管家采纳,获得10
8秒前
上官若男应助科研通管家采纳,获得10
8秒前
Hello应助科研通管家采纳,获得10
8秒前
Ava应助科研通管家采纳,获得30
8秒前
Zon发布了新的文献求助10
8秒前
鸣笛应助科研通管家采纳,获得30
8秒前
8秒前
8秒前
9秒前
9秒前
在水一方应助小白痴采纳,获得10
10秒前
hideyoshi发布了新的文献求助30
10秒前
LL关闭了LL文献求助
10秒前
CipherSage应助要减肥的香芦采纳,获得10
10秒前
王q完成签到,获得积分10
12秒前
欢喜念双发布了新的文献求助10
13秒前
13秒前
高分求助中
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
Effective Learning and Mental Wellbeing 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3974882
求助须知:如何正确求助?哪些是违规求助? 3519431
关于积分的说明 11198315
捐赠科研通 3255698
什么是DOI,文献DOI怎么找? 1797904
邀请新用户注册赠送积分活动 877237
科研通“疑难数据库(出版商)”最低求助积分说明 806219